ライフサイエンスコーパス: cytotoxic T-cell

1 filtrating CD4 helper T cells and CD8 memory cytotoxic T cells.

2 HLA-B27 of presenting antigenic peptides to cytotoxic T cells.

3 fect was associated with a reduced influx of cytotoxic T cells.

4 erized by HA-specific CD4 T helper 1 and CD8 cytotoxic T cells.

5 ing their interaction with SLAMF4-expressing cytotoxic T cells.

6 cells, plasma B cells, and memory helper and cytotoxic T cells.

7 s I loading and cell surface presentation to cytotoxic T cells.

8 modulate immune recognition by NK cells and cytotoxic T cells.

9 euronal death in the presence of appropriate cytotoxic T cells.

10 class I proteins that might be recognized by cytotoxic T cells.

11 xicity and long-term persistence provided by cytotoxic T cells.

12 ules display peptides at the cell surface to cytotoxic T cells.

13 thereby influencing antigen presentation to cytotoxic T cells.

14 vation of antigen-presenting cells and naive cytotoxic T cells.

15 ne production, and their capacities to prime cytotoxic T cells.

16 kidney and used PD-L1 to induce apoptosis of cytotoxic T cells.

17 ecreased infiltration of dendritic cells and cytotoxic T cells.

18 of TNFalpha and YAP1 and low infiltration of cytotoxic T cells.

19 mpaired function of natural killer cells and cytotoxic T cells.

20 tegies, for example those aimed at eliciting cytotoxic T cells.

21 nd to expansion of long-lived tumor-reactive cytotoxic T cells.

22 conclusion, female UCB comprises HY-specific cytotoxic T cells.

23 FN-gamma secreted by CD8+, antigen-specific, cytotoxic T cells.

24 recognition by the T cell receptor (TCR) of cytotoxic T cells.

25 ptides presented on MHC class I molecules to cytotoxic T cells.

26 tly, susceptibility to lysis by PR1-specific cytotoxic T cells.

27 d a decrease in Th1 and granzyme B-producing cytotoxic T cells.

28 e apoptosis of CD4(+) Th1 and Th17 cells and cytotoxic T cells.

29 tary mechanisms, including pathogen-specific cytotoxic T cells.

30 otherapy, and administration of EBV-specific cytotoxic T cells.

31 ne production and generate CD4(+) and CD8(+) cytotoxic T cells.

32 r the induction of relevant epitope-specific cytotoxic T cells.

33 cell surface as potential ligands for CD8(+) cytotoxic T cells.

34 id leukemia cells to generate tumor-specific cytotoxic T cells.

35 reduced expression of cytokines produced by cytotoxic T cells.

36 and targeted for elimination by Ag-specific cytotoxic T cells.

37 reduced signature of markers characterizing cytotoxic T cells.

38 and were infiltrated with mutation-specific cytotoxic T cells.

39 lated membrane attack complex, exotoxins, or cytotoxic T cells.

40 d promote progression through suppression of cytotoxic T cells.

41 rapy promotes the killing of cancer cells by cytotoxic T cells.

42 mumab induced robust increases in helper and cytotoxic T-cell absolute counts.

43 Helper and cytotoxic T cells accomplish focused secretion through t

44 h defective MHC class I expression, impaired cytotoxic T cell activation, and poor patient prognosis.

45 was normal, in vitro-generated EBV-specific cytotoxic T cell activity was reduced because of CD70 de

46 ells, and direct and indirect suppression of cytotoxic T cell activity.

47 increase in influenza nucleoprotein-specific cytotoxic T cell activity.

48 hese classes of therapeutics is dependent on cytotoxic T-cell activity and is associated with a reduc

49 unction and is a potential target to improve cytotoxic T-cell activity.Grail is an E3 ubiquitin ligas

50 ls and is necessary for efficient priming of cytotoxic T cells against dead cell-associated antigens.

51 Th and cytotoxic T cells also contained IL-26.

52 nse, interferon-gamma and rejection-induced, cytotoxic T cell and constitutive macrophage-associated

53 pecificity as HLA-A*0201/IMP(58-66)-specific cytotoxic T cells and bound neither to HLA-A*0201 nor th

54 ne response by providing help to B cells and cytotoxic T cells and by releasing different types of cy

55 surface of lymphoma cells for recognition by cytotoxic T cells and can serve as a novel target for de

56 n, but led to increased adhesion of alopecic cytotoxic T cells and enhanced T cell cytotoxicity in an

57 oteins pp65 and IE1 as important inducers of cytotoxic T cells and glycoprotein B (gB) as an importan

58 of mycobacterial-specific polyfunctional and cytotoxic T cells and higher concentrations of Th1 cytok

59 on and promoted elevations in tumor-specific cytotoxic T cells and IFN-gamma levels, while lowering I

60 recruit PA-CXCR4-expressing tumor-targeting cytotoxic T cells and improved the efficacy of adoptive

61 d that AC-NPs induced an expansion of CD8(+) cytotoxic T cells and increased both CD4(+)T/Treg and CD

62 ation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression.

63 DCs in vivo induced expansion of Ag-specific cytotoxic T cells and inhibited Foxp3(+) regulatory T ce

64 In cytotoxic T cells and natural killer (NK) cells, transie

65 The results showed increased activity of cytotoxic T cells and natural killer cells in BKVN and v

66 More importantly, PMVDS stimulated both cytotoxic T cells and natural killer cells of cell-media

67 nes, and adoptive transfer of tumor-specific cytotoxic T cells and natural killer cells, have been cl

68 imicrobial peptide (AMP) that is produced by cytotoxic T cells and natural killer cells.

69 cal proteins required for normal function of cytotoxic T cells and NK cells) or secondary (resulting

70 sponse in advanced thyroid cancers linked to cytotoxic T cells and NK cells.

71 tes the proliferation and differentiation of cytotoxic T cells and NK cells.

72 of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells.

73 vely kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2

74 (H)1) response, which leads to activation of cytotoxic T cells and reduction of immunosuppression.

75 Human GIFT4-licensed B cells primed cytotoxic T cells and specifically killed melanoma cells

76 tribute to the activation of intraepithelial cytotoxic T cells and the development of villous atrophy

77 ate a bispecific antibody designed to engage cytotoxic T cells and trigger tumor cell killing.

78 enal parenchyma by activated macrophages and cytotoxic T cells, and acute tubular injury.

79 ell compartment has more CD4 helper than CD8 cytotoxic T cells, and this is most evident looking at T

80 udies have shown that T helper cells but not cytotoxic T cells are critical for the disease pathology

81 CD8+ cytotoxic T cells are critical for viral clearance from

82 Tim-3(+) cytotoxic T cells are dysfunctional and are unable to se

83 to apoptosis stimuli and the persistence of cytotoxic T cells are essential factors for the outcome

84 Cytotoxic T cells are of central importance in the immun

85 s or HIV loads, suggesting that VZV-specific cytotoxic T cells are protective against HZ.

86 Although functionally competent cytotoxic, T cells are frequently observed in malignant

87 e cell types, while CD8(+) T cells (known as cytotoxic T cells) are major cells that provide immunity

88 ls of seven activation markers on helper and cytotoxic T cells as well as the percentage of CD4(+) CD

89 granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors resp

90 and progenitors in the presence of activated cytotoxic T cells, as occurs in human BM failure.

91 n are likely related to the intensity of the cytotoxic T-cell assault on the myenteric plexus.

92 terferon-enzyme-linked immunospot assay, and cytotoxic T-cell assay.

93 Immunomodulatory antibodies directed against cytotoxic T cell-associated antigen 4 (CTLA-4/CD152) and

94 g, cytolytic granule composition, type 1 CD8 cytotoxic T cell-associated effector molecules granzyme

95 on susceptibility of melanoma to killing by cytotoxic T cells, blocking SD-4 function enhanced the r

96 signaling provides costimulatory signals to cytotoxic T cells but also increases the frequency of re

97 virus replication initiated by HBV-specific cytotoxic T cells, but it significantly inhibited recrui

98 NO by inflammatory DCs and the activation of cytotoxic T cells by splenic CD8alpha(+) DCs.

99 nd in particular T helper (Th) 1, Th17, CD8+ cytotoxic T cells, CD19+ B cells and CD56+ natural kille

100 endritic cells (CD209(+)), T cells (CD3(+)), cytotoxic T cells (CD8(+)), and helper T cells (CD4(+))

101 11b+), increased dendritic cells (CD86+) and cytotoxic T cells (CD8+) in the p65 knockout (KO) mice.

102 e enriched and evade lysis by HLA-restricted cytotoxic T-cell clones.

103 h infiltrating CD4(+) T(H)1 cells and CD8(+) cytotoxic T cells constitute a positive prognostic sign

104 re consistent with a feedback model in which cytotoxic T cells control immune activation by killing d

105 imits vector reapplication, the expansion of cytotoxic T cells correlates with liver inflammation and

106 In addition, the proportion of NK and cytotoxic T cell (CTL) expressing perforin and granzyme

107 PCs) within tumors typically do not maintain cytotoxic T cell (CTL) function, despite engaging them.

108 ERK) antigen, the action of antigen-specific cytotoxic T cell (CTL) in vivo results in the emergence

109 HIV-1 often evades cytotoxic T cell (CTL) responses by generating variants

110 hetic subunit vaccines need to induce CD8(+) cytotoxic T cell (CTL) responses for effective vaccinati

111 ontrol of hepatitis C virus (HCV) infection, cytotoxic T cells (CTL) are pivotal, but persistence of

112 erated, adoptive therapy with virus-specific cytotoxic T cells (CTL) can be utilized.

113 How dendritic cells (DC) present Ag to cytotoxic T cells (CTL) without themselves being killed

114 In cytotoxic T cells (CTL), Akt, also known as protein kina

115 ells (DCs) are required for the induction of cytotoxic T cells (CTL).

116 umor target and cognate melanoma Ag-specific cytotoxic T cells (CTL).

117 iled map of IL-2 protein phosphorylations in cytotoxic T cells (CTL).

118 donorderived cytomegalovirus (CMV)-specific cytotoxic T cells (CTLs) and compare outcomes with a gro

119 program death-1 (PD-1) expression on CD8(+) cytotoxic T cells (CTLs) at the tumor site.

120 nhanced the frequency of T-helper/memory and cytotoxic T cells (CTLs) in peripheral blood mononuclear

121 se Peripheral blood-derived antigen-specific cytotoxic T cells (CTLs) provide a readily available sou

122 Cancer immunotherapy in which cytotoxic T cells (CTLs) target tumor-specific antigens

123 (n = 4), naive (n = 3) and activated (n = 3) cytotoxic T cells (CTLs), and natural killer (NK) (n = 4

124 of tumour antigens that can activate CD8(+) cytotoxic T cells (CTLs), but the microenvironment of es

125 rectly prime or cross-prime MHC I-restricted cytotoxic T cells (CTLs).

126 preproinsulin (PPI) peptide epitopes to CD8 cytotoxic T cells (CTLs).

127 esults suggest that broad, highly functional cytotoxic T cells (cytotoxic T lymphocytes [CTLs]) again

128 -PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism.

129 aves basement membrane proteins and promotes cytotoxic T cell diapedesis into inflamed tissue.

130 Thus, the cytokine acts to control cytotoxic T cell differentiation in lymphoid and periphe

131 ction of Runx3, a nuclear factor crucial for cytotoxic T cell differentiation.

132 lived memory CD8 T cells; however, effective cytotoxic T-cell differentiation occurred only in the pr

133 We show that cytotoxic T cells directed against the N-terminal peptid

134 which likely act to minimize liver damage by cytotoxic T cells during viral clearance.

135 led more efficient expansion of E75-specific cytotoxic T cells (E75-CTL).

136 se of cytokines by T-cell receptor-activated cytotoxic T cells engaged by BiTE antibodies and leading

137 T cell-specific coreceptor CD4 in helper and cytotoxic T cells exemplifies this process, with enhance

138 After stimulation, cytotoxic T cells exhibited decreased effector function

139 s are surrounded and invaded by CD8-positive cytotoxic T cells expressing the alphabeta-T cell recept

140 Consequently, alloreactive HLA-A2-specific cytotoxic T cells failed to recognize HLA-A2-expressing

141 ful platform for generating large numbers of cytotoxic T cells for cancer immunotherapy.

142 tractive method to generate large numbers of cytotoxic T cells for immunotherapy of cancer and viral

143 effective tools to isolate rare high-avidity cytotoxic T cells from patients for use in adoptive ther

144 Intraepithelial cytotoxic T cells from potential celiac disease patients

145 Intraepithelial cytotoxic T cells from relatives of patients with celiac

146 s study, we evaluated the role of mir-155 in cytotoxic T cell function.

147 e cells can similarly modulate the degree of cytotoxic T-cell function and activity in the tumour mic

148 creased expression of negative regulators of cytotoxic T-cell function.

149 glycosylation of alpha dystroglycan with the cytotoxic T cell glycan and increases the overexpression

150 glycosylation of alpha dystroglycan with the cytotoxic T cell glycan or increased expression of dystr

151 first time that resistance of kidney TEC to cytotoxic T-cell granzyme B-induced death in vitro and i

152 uccess; the use of autologous virus-specific cytotoxic T cells has proved effective as well.

153 ture types), and killer cells (consisting of cytotoxic T cells, helper T cells, effector B cells, and

154 of cancer but also can initiate an antitumor cytotoxic T-cell immune response.

155 nalyzed epithelial cells and intraepithelial cytotoxic T cells in family members of patients with cel

156 Spatial distribution of cytotoxic T cells in proximity to cancer cells correlate

157 In vitro, these cells capture cytotoxic T cells in signaling-competent conjugates but

158 duced strong activation of both TH cells and cytotoxic T cells in the COPD cohort.

159 ammatory infiltrate indicated a reduction of cytotoxic T cells in the post-treatment muscle biopsies

160 ectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.

161 d enhanced lysis of melanoma cells by CD8(+) cytotoxic T cells in vitro.

162 ed more potent IFN-gamma-producing and lytic cytotoxic T cells in wt mice compared with NS5A-Tg mice.

163 te an important role for TNF-alpha-producing cytotoxic T-cells in mediating the anti-cancer effects o

164 ectively; (3) increased CD4+ helper and CD8+ cytotoxic T-cells in the spleen; and (4) profound spleni

165 Cytotoxic T cells infiltrating tumors are thought to uti

166 virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy o

167 led gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-gamma (IFN-

168 with high levels of fibrosis and poor CD8(+) cytotoxic T cell infiltration.

169 SUNb-PM not only increased cytotoxic T-cell infiltration and decreased the number a

170 d-derived suppressor cells and inhibition of cytotoxic T-cell infiltration.

171 Binding and crosslinking of CEACAM-6 by cytotoxic T cells inhibited their activation and resulte

172 l. (2013) reprogram mature, antigen-specific cytotoxic T cells into induced pluripotent stem cells (i

173 tion of cross-protective immunoglobulins and cytotoxic T cells is a possible mechanism.

174 illance network of antibodies and sensitized cytotoxic T cells is the extraordinary incidence of lymp

175 IL-33, required for viral clearance by cytotoxic T cells, is generally expressed in vascular en

176 in blood cell composition (notably exhausted cytotoxic T cells), it is less clear what explains the o

177 ion, and also in cross-priming and licensing cytotoxic T cell killers in vivo.

178 dy, mimicking one of the major mechanisms of cytotoxic T cell killing, inhibits B cell receptor-media

179 ome patients with HLH or MAS lack defects in cytotoxic T cell killing.

180 A GrB inhibitor rescued SPI6(-/-) MSCs from cytotoxic T-cell killing.

181 IL-2 superkine induced superior expansion of cytotoxic T cells, leading to improved antitumour respon

182 elper T cells TH1 and TH2 serum antibody and cytotoxic T-cell levels compared to bolus controls.

183 fied as the cytokines responsible for CD8(+) cytotoxic T cell lineage specification in vivo.

184 We reasoned that concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoin

185 Ipilimumab, which is an anti-cytotoxic T-cell lymphocyte-4 monoclonal antibody, showe

186 rammed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 antibody) in pa

187 including the programmed death 1 (PD-1) and cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4

188 8+ lymphocyte infiltration and expression of cytotoxic T-cell markers and effector cytokines, similar

189 o investigate the association of CPS-induced cytotoxic T-cell markers with protection.

190 ockade that can be mediated by activation of cytotoxic T cells may be overcome in some tumor microenv

191 esented by Li et al shows that memory CD8(+) cytotoxic T cells mediate fibrosis via the secretion of

192 mine the mechanisms by which intraepithelial cytotoxic T cells mediate tissue destruction in celiac d

193 SCs with MigR1-SPI6 also protected MSCs from cytotoxic T cell-mediated death in vitro.

194 ) cell frequency correlated with inefficient cytotoxic T cell-mediated killing of HTLV-1-infected cel

195 significant enhancement of Th1-mediated and cytotoxic T-cell-mediated antitumor immunity.

196 Ultimately, these events promote cytotoxic T-cell-mediated clearance of tumour cells, whi

197 e tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targ

198 urface receptor programmed death 1 (PD-1) on cytotoxic T cells mediates to their tolerance.

199 nce of local immune suppression, transferred cytotoxic T cells more effectively controlled tumors in

200 cells, we were able to stimulate peripheral cytotoxic T cells obtained from colorectal cancer patien

201 Effective immune surveillance by CD8(+) cytotoxic T cells of intracellular microbes and cancer d

202 enhancing the recruitment of tumor-specific cytotoxic T cells offers therapeutic potential.

203 a is a chronic clonal lymphoproliferation of cytotoxic T cells often associated with autoimmune disea

204 e relevance of Bim in regulating survival of cytotoxic T cells or induction of hepatocyte death has o

205 emia is characterized by clonal expansion of cytotoxic T cells or natural killer cells.

206 unosuppressive agents, rituximab, autologous cytotoxic T cells, or cytotoxic chemotherapy often resul

207 Monocyte, natural killer (NK) cell, and cytotoxic T-cell p11 levels were positively associated w

208 his ER-associated chaperone in maintaining a cytotoxic T cell phenotype.

209 immunological control, primarily mediated by cytotoxic T cells, plays a critical role in preventing C

210 or (89)Zr-immuno-PET detection of helper and cytotoxic T cell populations.

211 associated with infiltrating regulatory and cytotoxic T-cell populations, suggesting distinct immuno

212 delayed SIVsmE660 acquisition; SIV-specific cytotoxic T cells, prechallenge CD4(+) effector memory,

213 aining expression of an efficient type 1 CD8 cytotoxic T cell program (granzyme B(+), IFN-gamma(+)).

214 a and rejection induced (GRIT), quantitative cytotoxic T-cell (QCAT), quantitative constitutive and a

215 We here demonstrate that cytotoxic T cells reacted against myeloma antigens when

216 ereby impeding presentation of viral Ags and cytotoxic T cell recognition of the infected cell.

217 tation by DCs to the induction of anti-viral cytotoxic T cells remains controversial.

218 ecently demonstrated that differentiation of cytotoxic T cells requires cooperation between T-cell re

219 Effective immune surveillance by cytotoxic T cells requires newly synthesized polypeptide

220 usive expression of CD4 or CD8 in helper and cytotoxic T cells, respectively.

221 y elicit a viral peptide/self-HLA restricted cytotoxic T cell response in humans.

222 ENCA mitochondrial lysate vaccine elicited a cytotoxic T cell response in vivo and conferred durable

223 However, the cytotoxic T cell response may also be required after cur

224 plays an important role in the dysregulated cytotoxic T cell response to HIV-1, and in silico algori

225 We also show that the cytotoxic T cell response was totally dependent on CD4(+

226 s) and thus stimulate a tumor-specific, CD8+ cytotoxic T cell response.

227 responses, with a weaker than desired CD8(+) cytotoxic T cell response.

228 sistent human pathogen, kept in check by the cytotoxic T cell response.

229 mors by generating a systemic tumor-specific cytotoxic T cell response.

230 oparticle, PC7A NP, which generates a strong cytotoxic T-cell response with low systemic cytokine exp

231 es and high viremia, Cl13 generated a robust cytotoxic T-cell response, resulting in thrombocytopenia

232 AAV genomes implicated pathways besides the cytotoxic T-cell response.

233 Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumor-specific

234 t MTM, depletion restores tumor-infiltrating cytotoxic T cell responses and suppresses tumor growth.

235 The cytotoxic T cell responses are categorically needed agai

236 HIV-1-specific cytotoxic T cell responses are expanded during advanced

237 lated cancers are usually designed to elicit cytotoxic T cell responses by targeting the HPV-16 E7 on

238 rsistent-latent virus that elicits different cytotoxic T cell responses characterized as acute resolv

239 played by these alleles and drive helper and cytotoxic T cell responses in patients with Parkinson's

240 ion of this receptor led to enhanced in vivo cytotoxic T cell responses to apoptotic cell-associated

241 booster vaccination significantly increased cytotoxic T cell responses to subdominant highly conserv

242 class I expression and its ability to elicit cytotoxic T cell responses.

243 tumor specific and have been shown to elicit cytotoxic T cell responses.

244 ll responses and provide help for B cell and cytotoxic T cell responses.

245 hey induce strong protective and therapeutic cytotoxic T cell responses.

246 geting immunomodulatory receptors to promote cytotoxic T cell responses.

247 ins may enhance vaccine induction of optimal cytotoxic T cell responses.

248 ain source of alloantigen that drives CD8(+) cytotoxic T cell responses.

249 pamycin completely abolished vaccine-induced cytotoxic T-cell responses and therapeutic activity.

250 th the ability to stimulate antigen-specific cytotoxic T-cell responses during tumor development.

251 Long-lived cytotoxic T-cell responses were detected against peptide

252 Functional cytotoxic T-cell responses, including responses to one m

253 nsfected and endogenous antigens and enhance cytotoxic T-cell responses, indicating that these enzyme

254 p shape the antigenic peptide repertoire and cytotoxic T-cell responses.

255 s to cross-present antigens and to stimulate cytotoxic T-cell responses.

256 cells and are fully equipped to cross-prime cytotoxic T-cell responses.

257 okines such as IL-12, and display suboptimal cytotoxic T-cell responses.

258 genes associated with acute inflammatory or cytotoxic T-cell responses.

259 ar focus on the development of antibacterial cytotoxic T-cell responses.

260 was associated with induction of a prominent cytotoxic T-cell signature.

261 developed this molecular strategy to render cytotoxic T cells specific for fungi.

262 lines, together with engineered RMS-directed cytotoxic T cells specific for the fetal acetylcholine r

263 Cytotoxic T cells substantially contribute to the contro

264 sociated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR c

265 ing cells increased over time exclusively on cytotoxic T cells, T-helper cells, and regulatory T cell

266 Here we identified a specialized group of cytotoxic T cells (TC cells) that expressed the chemokin

267 Cytotoxic T cells (Tc) use perforin and granzyme B (gzmB

268 actors T-bet and Eomesodermin (Eomes) in CD8 cytotoxic T cells (Tc), which are key in rejecting tumor

269 ILCs (ILC1 and natural killer cells), CD8(+) cytotoxic T cells (TC1), and CD4(+) TH1 cells, which pro

270 hese cells, which we have called 'follicular cytotoxic T cells' (TFC cells), required the transcripti

271 -fold higher death rate by primed allogeneic cytotoxic T cells than did wild-type MSCs.

272 Cytotoxic T cells that are present in tumors and capable

273 s) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC

274 m this provirus are immunogenic, stimulating cytotoxic T cells that kill RCC cells in vitro and in vi

275 e data reinforce and extend previous data on cytotoxic T cells that one of the principal functions of

276 eventually, the activation of tumor-specific cytotoxic T cells, their recruitment into the tumor site

277 rate, as well as Epstein-Barr virus-specific cytotoxic T-cell therapy.

278 ze ( approximately 50 kDa) that can redirect cytotoxic T cells through simultaneous binding of tumor

279 apture them and induce tolerance of specific cytotoxic T cells through unknown mechanisms.

280 lls and tumor-associated antigens to recruit cytotoxic T cells to cancer cells, are a promising new a

281 The resulting alphaCLL1-alphaCD3 recruits cytotoxic T cells to CLL1 positive cells, and demonstrat

282 important for adoptively transferred CD8(+) cytotoxic T cells to destroy tumors.

283 ically programmed biAbs aimed at redirecting cytotoxic T cells to eliminate cancer cells.

284 h epithelial stress to allow intraepithelial cytotoxic T cells to kill epithelial cells and induce vi

285 A failure of cytotoxic T cells to limit or contract inflammatory resp

286 onclassical Qa-1(b)-peptide complexes direct cytotoxic T cells to targets with defective antigen proc

287 represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing targe

288 ive transfer of donor-derived virus-specific cytotoxic T cells (VSTs) is a strategy to rapidly restor

289 ive transfer of donor-derived viral-specific cytotoxic T-cells (VSTs) is an effective treatment for c

290 d Th17-associated transcription factors, and cytotoxic T cells was found in the gastric lamina propri

291 ination of Nlrc5(Delta/Delta) lymphocytes by cytotoxic T cells was markedly reduced and, in addition,

292 known about resistance mechanisms of RMS to cytotoxic T cells, we investigated RMS cell lines and bi

293 Last, tumor-specific cytotoxic T cells were also found to be activated in viv

294 Strikingly, cytotoxic T cells were generated against 37 out of 50 pe

295 Intraepithelial cytotoxic T cells were isolated and levels of inhibitory

296 CD8+ CD57+ cytotoxic T cells were persistently increased after ther

297 macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and

298 Furthermore, activation of cytotoxic T cells with combination therapy mediated the

299 BV viral loads and impaired EBV-specific CD8 cytotoxic T cells, with impaired cytokine responses to E

300 umor immunity by directly stimulating CD8(+) cytotoxic T cells, with the potential to increase curati